Literature DB >> 11194822

Percutaneous stenting of an latrogenic superior mesenteric artery dissection complicating suprarenal aortic aneurysm repair.

P Desgranges1, P A Bourriez, A d'Audiffret, T Zubilewicz, D Mathieu, J P Becquemin, H Kobeiter.   

Abstract

PURPOSE: To report endovascular repair of an iatrogenic superior mesenteric artery (SMA) dissection caused by a balloon occlusion catheter. CASE REPORT: A 68-year-old man with a suprarenal aortic aneurysm underwent conventional prosthetic replacement, during which visceral artery back bleeding was controlled with balloon occlusion catheters. Six hours postoperatively, the patient experienced an episode of bloody diarrhea with abdominal pain and tenderness and mild metabolic acidosis. Colonoscopy revealed colitis (grade I) without necrosis of the right and left colon. An emergent abdominal computed tomographic scan showed signs of mesenteric ischemia with bowel dilatation and SMA wall hematoma; angiography identified a dissection 1 cm distal to the SMA origin. An Easy Wallstent was deployed percutaneously, successfully reestablishing SMA patency. The postoperative course was uneventful, and the patient remains asymptomatic with a patent SMA stent and aortic graft at 1 year.
CONCLUSIONS: latrogenic SMA dissection should be suspected after suprarenal aortic aneurysm repair if signs of mesenteric ischemia arise. Prompt and thorough imaging studies are necessary to confirm the diagnosis and assess the potential for an endoluminal treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11194822     DOI: 10.1177/152660280000700611

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  1 in total

Review 1.  Diagnosis and Management of Isolated Superior Mesenteric Artery Dissection: A Systematic Review and Meta-Analysis.

Authors:  Waqas Ullah; Maryam Mukhtar; Hafez Mohammad Abdullah; Mamoon Ur Rashid; Asrar Ahmad; Abu Hurairah; Usman Sarwar; Vincent M Figueredo
Journal:  Korean Circ J       Date:  2019-05       Impact factor: 3.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.